Do patients receiving chronic glucocorticoids (e.g., prednisone ≥5 mg/day for ≥2 weeks) need additional stress‑dose steroids when they develop sepsis?

Yes, patients on chronic steroids need stress-dose corticosteroids when they develop sepsis or septic shock.

Patients receiving chronic glucocorticoids (≥5 mg/day prednisone for ≥2 weeks) require stress-dose corticosteroid supplementation when they develop sepsis, particularly septic shock, due to hypothalamic-pituitary-adrenal (HPA) axis suppression that prevents adequate endogenous cortisol response to critical illness.

The Critical Distinction: Chronic Steroid Users vs. Steroid-Naive Patients

Your question addresses two separate but related issues that must be distinguished:

1. Stress-Dose Coverage for Chronic Steroid Users (Your Primary Question)

Patients on chronic corticosteroids develop HPA axis suppression, meaning their adrenal glands cannot mount an adequate stress response during sepsis 1. The FDA labeling explicitly states: "Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during and after the stressful situation" 1.

This type of relative insufficiency may persist for up to 12 months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. If the patient is receiving steroids already, dosage may have to be increased 1.

2. Therapeutic Corticosteroids for Septic Shock (Separate Issue)

For steroid-naive patients with septic shock, guidelines suggest using corticosteroids when shock is refractory to fluids and moderate-to-high-dose vasopressors 2.

Practical Algorithm for Chronic Steroid Users with Sepsis

Step 1: Identify Patients at Risk

• Any patient taking ≥5 mg prednisone daily (or equivalent) for ≥2 weeks
• Patients who stopped steroids within the past 12 months 1
• Those on alternate-day therapy or any chronic corticosteroid regimen 1

Step 2: Assess Sepsis Severity

For Sepsis WITHOUT Shock:

• Continue baseline chronic steroid dose at minimum
• Consider modest increase (e.g., double the maintenance dose) during acute illness
• The 2017 SCCM/ESICM guidelines suggest against adding therapeutic-dose corticosteroids for sepsis without shock 2, but this refers to therapeutic dosing in steroid-naive patients, not stress-dose coverage for chronic users

For Septic Shock (requiring vasopressors):

• Immediately increase to stress-dose hydrocortisone: 200-300 mg/day IV (divided doses or continuous infusion) 2, 3
• This represents both stress-dose coverage for HPA suppression AND therapeutic benefit for shock
• The 2024 focused update provides a conditional recommendation to administer corticosteroids for septic shock 3
• Optimal dosing appears to be approximately 260 mg/day of hydrocortisone or equivalent 4

Step 3: Duration and Tapering

• Continue stress-dose for ≥3 days at full dose 2
• Maintain until shock resolves and vasopressors are discontinued
• Taper gradually back to baseline chronic dose—never stop abruptly 1
• The FDA explicitly warns: "Avoid abrupt withdraw of therapy" 1

Evidence Supporting This Approach

The rationale combines two bodies of evidence:

HPA Axis Suppression (Drug Label Evidence): The FDA labeling clearly establishes that chronic corticosteroid use causes "reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment" 1. This creates an absolute need for stress-dose coverage during critical illness.

Therapeutic Benefit in Septic Shock: The 2017 SCCM/ESICM guidelines recommend using corticosteroids in septic shock unresponsive to fluids and moderate-to-high-dose vasopressors (conditional recommendation, low-quality evidence) 2. The 2024 update strengthened this with a conditional recommendation for corticosteroids in septic shock 3. A 2025 Cochrane review found corticosteroids probably reduce 28-day mortality (RR 0.89,95% CI 0.84-0.95; moderate certainty) 5.

Critical Pitfalls to Avoid

Pitfall #1: Assuming Chronic Dose is Sufficient The maintenance dose (e.g., 5-10 mg prednisone daily) is inadequate for septic stress. Failure to increase dosing can precipitate acute adrenal crisis with refractory hypotension 1.

Pitfall #2: Abrupt Discontinuation Never stop corticosteroids abruptly in septic patients on chronic therapy. This can cause life-threatening adrenal crisis even after clinical improvement 1.

Pitfall #3: Forgetting the 12-Month Window Patients who stopped chronic steroids within the past year remain at risk for inadequate stress response and may need stress-dose coverage 1.

Pitfall #4: Confusing Stress-Dose with Therapeutic Dosing The evidence against corticosteroids in "sepsis without shock" 2 applies to therapeutic use in steroid-naive patients, not stress-dose coverage for those with HPA suppression.

Specific Dosing Recommendations

Hydrocortisone (preferred):

• Stress-dose: 200-300 mg/day IV (50 mg IV q6h or continuous infusion)
• Duration: ≥3 days, continue until shock resolves
• Taper over several days back to baseline chronic dose

Prednisone Equivalent Conversion:

• If patient takes prednisone 10 mg daily chronically
• Stress-dose equivalent: ~50-75 mg prednisone daily (or switch to IV hydrocortisone)
• Hydrocortisone 20 mg = prednisone 5 mg (4:1 ratio)

Adverse Effects to Monitor

Corticosteroids in sepsis increase risk of:

• Hyperglycemia (RR 1.21; high certainty) 6
• Hypernatremia (RR 1.59; moderate certainty) 6
• Possibly neuromuscular weakness (RR 1.22; low certainty) 6

However, they probably do not increase gastrointestinal bleeding or secondary infections 6.

Bottom Line

For patients on chronic steroids who develop sepsis: Always provide stress-dose coverage. For septic shock specifically, use hydrocortisone 200-300 mg/day IV for ≥3 days, which serves dual purposes—preventing adrenal crisis from HPA suppression and providing therapeutic benefit for shock reversal 2, 1, 3. This is not optional; it is a physiologic necessity based on established endocrine principles and FDA-mandated prescribing information.